What You Should Know:
– Harrison.ai, a global healthtech company, today announced the completion of a $112M in Series C funding round co-led by Aware Super, ECP, and existing investor Horizons Ventures. New investors, including Australia’s National Reconstruction Fund Corporation (NRFC), Ord Minnett, and Wollemi Capital Group, also participated, along with existing investors Blackbird Ventures and Alpha JWC Ventures. This brings Harrison.ai’s total capital raised to date to over $240M.
– The investment will fuel the company’s expansion into the United States, fuel its product roadmap, and continue its growth in the UK, EMEA, and APAC regions.
Advanced AI Solutions for Cancer Detection and Other Critical Illnesses
Harrison.ai’s technology leverages AI to analyze medical images, such as CT scans and X-rays, to assist clinicians in detecting signs of cancer and other critical illnesses earlier and more accurately. This technology has the potential to revolutionize healthcare by improving diagnostic accuracy, reducing treatment delays, and saving lives.
Harrison.ai aims to address the growing demand for equitable and effective healthcare by addressing two key challenges:
- Shortage of skilled clinicians: The global shortage of radiologists and pathologists is a significant barrier to timely and accurate diagnosis. Harrison.ai’s technology can help alleviate this burden by augmenting human capabilities.
- Disparities in access to care: Many regions, both developed and underdeveloped, lack access to advanced diagnostic services. Harrison.ai’s solutions can help bridge this gap by providing remote access to diagnostic expertise.
Early Detection and Improved Outcomes
Harrison.ai’s technology has demonstrated significant potential for early detection and improved clinical outcomes. Studies have shown that Harrison.ai’s AI for chest radiography can aid in the early detection of lung cancer, with over 32% of cases being diagnosed sooner than conventional methods. This early detection can lead to more effective treatment options and improved patient outcomes.
Global Expansion and Partnerships
Harrison.ai is establishing a North American presence in Boston to support its growth in the United States. The company has already received 12 FDA clearances and one of its CT Brain algorithms has FDA Breakthrough Device Designation and Medicare reimbursement through the New Technology Add-on Payment (NTAP).
Harrison.ai has also formed partnerships with leading healthcare institutions and organizations worldwide. For example, it has been selected by the Danish public healthcare system to help clinicians deliver better outcomes and is powering all CT Brain scans across public accident and emergency (A&E) systems in Hong Kong
